Literature DB >> 10581076

Clinical applications of angiogenic growth factors and their inhibitors.

N Ferrara1, K Alitalo.   

Abstract

Promoting the formation of new collateral vessels in ischemic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of cardiovascular medicine. Conversely, inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes. These concepts are being tested now in clinical trials.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10581076     DOI： 10.1038/70928

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  196 in total

1.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

Authors:  C J Kuo; F Farnebo; E Y Yu; R Christofferson; R A Swearingen; R Carter; H A von Recum; J Yuan; J Kamihara; E Flynn; R D'Amato; J Folkman; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Vascular growth factors in cerebral ischemia.

Authors:  S D Croll; S J Wiegand
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

Review 3.  Angiogenesis in inflammatory joint disease: a target for therapeutic intervention.

Authors:  P E Brenchley
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

4.  Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.

Authors:  Christiana Ruhrberg; Holger Gerhardt; Matthew Golding; Rose Watson; Sofia Ioannidou; Hajime Fujisawa; Christer Betsholtz; David T Shima
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

5.  Vascular endothelial growth factor and fibroblast growth factor 2 delivery from spinal cord bridges to enhance angiogenesis following injury.

Authors:  Laura De Laporte; Anne des Rieux; Hannah M Tuinstra; Marina L Zelivyanskaya; Nora M De Clerck; Andrei A Postnov; Véronique Préat; Lonnie D Shea
Journal:  J Biomed Mater Res A       Date:  2011-05-31       Impact factor: 4.396

6.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

7.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

8.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart.

Authors:  H Su; R Lu; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

9.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 10.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.